Flexion Therapeutics, Inc. (FLXN) Given “Buy” Rating at Laidlaw
Flexion Therapeutics, Inc. (NASDAQ:FLXN)‘s stock had its “buy” rating restated by Laidlaw in a research note issued on Tuesday. They currently have a $38.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $35.00. Laidlaw’s price target would indicate a potential upside of 34.56% from the stock’s previous close.
Several other analysts have also recently issued reports on FLXN. Cantor Fitzgerald set a $40.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research report on Tuesday, June 27th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $44.00 target price on shares of Flexion Therapeutics in a research report on Friday, July 7th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $88.50.
Flexion Therapeutics (FLXN) traded down 2.30% during midday trading on Tuesday, hitting $27.59. The company had a trading volume of 3,210,831 shares. The stock has a 50 day moving average price of $24.85 and a 200 day moving average price of $22.63. Flexion Therapeutics has a 52 week low of $15.93 and a 52 week high of $32.25. The company’s market capitalization is $880.26 million.
Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Equities analysts forecast that Flexion Therapeutics will post ($3.75) earnings per share for the current fiscal year.
In other Flexion Therapeutics news, insider Yamo Deniz acquired 3,000 shares of the stock in a transaction dated Friday, September 1st. The stock was purchased at an average price of $24.15 per share, with a total value of $72,450.00. Following the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $120,750. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders bought a total of 5,375 shares of company stock valued at $131,575 in the last three months. Insiders own 15.98% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Fiduciary Trust Co. acquired a new stake in shares of Flexion Therapeutics in the 2nd quarter worth $101,000. IFP Advisors Inc boosted its position in shares of Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares in the last quarter. Advisor Group Inc. boosted its position in shares of Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares in the last quarter. Voya Investment Management LLC boosted its position in shares of Flexion Therapeutics by 25.8% in the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after purchasing an additional 2,651 shares in the last quarter. Finally, BB&T Securities LLC acquired a new stake in shares of Flexion Therapeutics in the 2nd quarter worth $289,000. 83.26% of the stock is owned by hedge funds and other institutional investors.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.